Pharmaceutical Benefits Advisory Committee (PBAC) consultation on Edaravone
04 September 2023The PBAC is currently accepting submissions regarding the inclusion of Edaravone (RADICAVA®) on the Pharmaceutical Benefits Scheme.
The PBAC is currently accepting submissions regarding the inclusion of Edaravone (RADICAVA®) on the Pharmaceutical Benefits Scheme.
We are excited to announce the recipients of the Daniel McLoone Major Research Initiative jointly funded by MND Research Australia (MNDRA) and FightMND.
The 2023 Clinical Research Learning Institute will be held on 13-14 October, 2023.
$46M
invested in research to find treatments and a cure for motor neurone disease
2,100
Australians currently living with MND who we support through investment in research, care and advocacy
148
evidence-based MND information materials developed to advance care and quality of life